| ADC overall cohort | ADC neuroendocrine marker positive | ADC neuroendocrine marker negative | p value | |||
---|---|---|---|---|---|---|---|
n | % | n | % | n | % | Â | |
Patients | 627 | 100 | 110 | 100 | 517 | 100 | Â |
Gender | |||||||
 Male | 365 | 58 | 67 | 61 | 298 | 58 | 0.528 |
 Female | 262 | 42 | 43 | 39 | 219 | 42 |  |
Age, median y (range) | 63 (30–89) | 63 (41–84) | 63 (30–89) | 0.373 | |||
TNM | |||||||
 pT | |||||||
  pT1 | 127 | 20 | 25 | 23 | 102 | 20 | 0.535 |
  pT2 | 388 | 62 | 63 | 57 | 325 | 63 |  |
  pT3 | 94 | 15 | 17 | 15 | 77 | 15 |  |
  pT4 | 18 | 3 | 5 | 5 | 13 | 3 |  |
 pN | |||||||
  pN0 | 314 | 50 | 63 | 57 | 251 | 49 | 0.068a |
  pN1 | 94 | 15 | 14 | 13 | 80 | 15 |  |
  pN2 | 192 | 31 | 28 | 25 | 164 | 32 |  |
  pN3 | 5 | 1 | 0 | 0 | 5 | 1 |  |
  pNX | 22 | 4 | 5 | 5 | 17 | 3 |  |
 pM | |||||||
  pM1 | 26 | 4 | 2 | 2 | 24 | 5 |  |
  pMX | 601 | 96 | 108 | 98 | 493 | 95 |  |
Stage | |||||||
 I | 254 | 41 | 46 | 42 | 208 | 40 | 0.153b |
 II | 130 | 21 | 29 | 26 | 101 | 20 |  |
 III | 217 | 35 | 33 | 30 | 184 | 36 |  |
 IV | 26 | 4 | 2 | 2 | 24 | 5 |  |
Genetic aberrations | |||||||
 KRAS | 147c | 36 | 29d | 36 | 118e | 36 | 0.732f |
 EGFR | 64c | 16 | 10d | 8 | 52 | 16 |  |
 BRAF | 14c | 3 | 2d | 3 | 12 | 4 |  |
 ROS1 | 5c | 1 | 1d | 1 | 4 | 1 |  |
 ALK | 5c | 1 | 0d | 0 | 5 | 2 |  |